Loading…
Gabapentin Antinociception in Mice with Acute Herpetic Pain Induced by Herpes Simplex Virus Infection
The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain. Transdermal infection with herpes simplex virus type-1 (HSV-1) produced nociceptive hypersensitivity of the infected hind paw to innocuous...
Saved in:
Published in: | The Journal of pharmacology and experimental therapeutics 2001-02, Vol.296 (2), p.270-275 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 275 |
container_issue | 2 |
container_start_page | 270 |
container_title | The Journal of pharmacology and experimental therapeutics |
container_volume | 296 |
creator | Takasaki, Ichiro Andoh, Tsugunobu Nojima, Hiroshi Shiraki, Kimiyasu Kuraishi, Yasushi |
description | The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain. Transdermal infection with herpes simplex virus type-1 (HSV-1) produced nociceptive hypersensitivity of the infected hind paw to innocuous (allodynia) and noxious mechanical stimulation (hyperalgesia) with von Frey filaments. Systemic administration of gabapentin (10–100 mg/kg, peroral) produced a dose-dependent inhibition of both allodynia and hyperalgesia; gabapentin (30–300 mg/kg) did not affect locomotor activity. Intrathecal injection of gabapentin (10–100 μg/animal) also attenuated dose dependently both nociceptive hypersensitivities. In contrast, intraplantar, intracisternal, and intracerebroventricular administration of gabapentin (10–100 μg/animal) had no effect on the HSV-1-induced nociceptive hypersensitivities. Pretreatment with naltrexone (1 mg/kg) inhibited antinociceptive effect of morphine (5 mg/kg), but not gabapentin (100 mg/kg). Repeated administration of morphine (5 mg/kg, four times) led to tolerance of antinociceptive action, whereas gabapentin (100 mg/kg, four times) had antinociceptive effect even after the forth administration. The present results suggest that gabapentin is effective in the treatment of acute herpetic pain without apparent adverse effects, and analgesic action of gabapentin is mainly mediated by actions on the spinal cord. |
doi_str_mv | 10.1016/S0022-3565(24)38784-1 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70631873</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022356524387841</els_id><sourcerecordid>70631873</sourcerecordid><originalsourceid>FETCH-LOGICAL-e294t-d661d36a529ecfd652bd0b8af6aa87299daede9e40276f5f6eb0aba3d366ae5a3</originalsourceid><addsrcrecordid>eNpFkUlPwzAQhS0EgrL8BJBPCA4BL4mTnFBVsUkgkFiuI8eeUKNsxAnQf49LWS4e2e-bJ888QvY5O-GMq9MHxoSIZKKSIxEfyyzN4oivkQlPBI8YZ3KdTP6QLbLt_StjPI6V3CRbnHPFFEsnBC91oTtsBtfQ6fJsjTPYDa5taHi6DRf64YY5nZpxQHqFfYeDM_ReB_W6saNBS4vFSvD0wdVdhZ_02fWjD3qJZmm1SzZKXXnc-6k75Oni_HF2Fd3cXV7PpjcRijweIqsUt1LpRORoSqsSUVhWZLpUWmepyHOr0WKOMROpKpNSYcHC92XoURoTLXfI4cq369u3Ef0AtfMGq0o32I4eUqYkz1IZwIMfcCxqtND1rtb9An4X8-80dy_zD9cjdHPd19q0VfuyAJErECBSFsCzFYhhrneHPXjjsAlrCU1mANs64AyWmcF3ZrAMBEQM35kBl181_ojY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70631873</pqid></control><display><type>article</type><title>Gabapentin Antinociception in Mice with Acute Herpetic Pain Induced by Herpes Simplex Virus Infection</title><source>Freely Accessible Journals</source><creator>Takasaki, Ichiro ; Andoh, Tsugunobu ; Nojima, Hiroshi ; Shiraki, Kimiyasu ; Kuraishi, Yasushi</creator><creatorcontrib>Takasaki, Ichiro ; Andoh, Tsugunobu ; Nojima, Hiroshi ; Shiraki, Kimiyasu ; Kuraishi, Yasushi</creatorcontrib><description>The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain. Transdermal infection with herpes simplex virus type-1 (HSV-1) produced nociceptive hypersensitivity of the infected hind paw to innocuous (allodynia) and noxious mechanical stimulation (hyperalgesia) with von Frey filaments. Systemic administration of gabapentin (10–100 mg/kg, peroral) produced a dose-dependent inhibition of both allodynia and hyperalgesia; gabapentin (30–300 mg/kg) did not affect locomotor activity. Intrathecal injection of gabapentin (10–100 μg/animal) also attenuated dose dependently both nociceptive hypersensitivities. In contrast, intraplantar, intracisternal, and intracerebroventricular administration of gabapentin (10–100 μg/animal) had no effect on the HSV-1-induced nociceptive hypersensitivities. Pretreatment with naltrexone (1 mg/kg) inhibited antinociceptive effect of morphine (5 mg/kg), but not gabapentin (100 mg/kg). Repeated administration of morphine (5 mg/kg, four times) led to tolerance of antinociceptive action, whereas gabapentin (100 mg/kg, four times) had antinociceptive effect even after the forth administration. The present results suggest that gabapentin is effective in the treatment of acute herpetic pain without apparent adverse effects, and analgesic action of gabapentin is mainly mediated by actions on the spinal cord.</description><identifier>ISSN: 0022-3565</identifier><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1016/S0022-3565(24)38784-1</identifier><identifier>PMID: 11160607</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acetates - pharmacology ; Amines ; Analgesics - pharmacology ; Animals ; Behavior, Animal - drug effects ; Cyclohexanecarboxylic Acids ; Drug Tolerance ; Female ; gamma-Aminobutyric Acid ; Herpes Simplex - complications ; Herpes Simplex - virology ; Herpesvirus 1, Human ; Hyperalgesia - drug therapy ; Mice ; Mice, Inbred BALB C ; Motor Activity - drug effects ; Naltrexone - pharmacology ; Narcotic Antagonists - pharmacology ; Pain - drug therapy ; Pain - etiology</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2001-02, Vol.296 (2), p.270-275</ispartof><rights>2001 American Society for Pharmacology and Experimental Therapeutics</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11160607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takasaki, Ichiro</creatorcontrib><creatorcontrib>Andoh, Tsugunobu</creatorcontrib><creatorcontrib>Nojima, Hiroshi</creatorcontrib><creatorcontrib>Shiraki, Kimiyasu</creatorcontrib><creatorcontrib>Kuraishi, Yasushi</creatorcontrib><title>Gabapentin Antinociception in Mice with Acute Herpetic Pain Induced by Herpes Simplex Virus Infection</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain. Transdermal infection with herpes simplex virus type-1 (HSV-1) produced nociceptive hypersensitivity of the infected hind paw to innocuous (allodynia) and noxious mechanical stimulation (hyperalgesia) with von Frey filaments. Systemic administration of gabapentin (10–100 mg/kg, peroral) produced a dose-dependent inhibition of both allodynia and hyperalgesia; gabapentin (30–300 mg/kg) did not affect locomotor activity. Intrathecal injection of gabapentin (10–100 μg/animal) also attenuated dose dependently both nociceptive hypersensitivities. In contrast, intraplantar, intracisternal, and intracerebroventricular administration of gabapentin (10–100 μg/animal) had no effect on the HSV-1-induced nociceptive hypersensitivities. Pretreatment with naltrexone (1 mg/kg) inhibited antinociceptive effect of morphine (5 mg/kg), but not gabapentin (100 mg/kg). Repeated administration of morphine (5 mg/kg, four times) led to tolerance of antinociceptive action, whereas gabapentin (100 mg/kg, four times) had antinociceptive effect even after the forth administration. The present results suggest that gabapentin is effective in the treatment of acute herpetic pain without apparent adverse effects, and analgesic action of gabapentin is mainly mediated by actions on the spinal cord.</description><subject>Acetates - pharmacology</subject><subject>Amines</subject><subject>Analgesics - pharmacology</subject><subject>Animals</subject><subject>Behavior, Animal - drug effects</subject><subject>Cyclohexanecarboxylic Acids</subject><subject>Drug Tolerance</subject><subject>Female</subject><subject>gamma-Aminobutyric Acid</subject><subject>Herpes Simplex - complications</subject><subject>Herpes Simplex - virology</subject><subject>Herpesvirus 1, Human</subject><subject>Hyperalgesia - drug therapy</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Motor Activity - drug effects</subject><subject>Naltrexone - pharmacology</subject><subject>Narcotic Antagonists - pharmacology</subject><subject>Pain - drug therapy</subject><subject>Pain - etiology</subject><issn>0022-3565</issn><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNpFkUlPwzAQhS0EgrL8BJBPCA4BL4mTnFBVsUkgkFiuI8eeUKNsxAnQf49LWS4e2e-bJ888QvY5O-GMq9MHxoSIZKKSIxEfyyzN4oivkQlPBI8YZ3KdTP6QLbLt_StjPI6V3CRbnHPFFEsnBC91oTtsBtfQ6fJsjTPYDa5taHi6DRf64YY5nZpxQHqFfYeDM_ReB_W6saNBS4vFSvD0wdVdhZ_02fWjD3qJZmm1SzZKXXnc-6k75Oni_HF2Fd3cXV7PpjcRijweIqsUt1LpRORoSqsSUVhWZLpUWmepyHOr0WKOMROpKpNSYcHC92XoURoTLXfI4cq369u3Ef0AtfMGq0o32I4eUqYkz1IZwIMfcCxqtND1rtb9An4X8-80dy_zD9cjdHPd19q0VfuyAJErECBSFsCzFYhhrneHPXjjsAlrCU1mANs64AyWmcF3ZrAMBEQM35kBl181_ojY</recordid><startdate>20010201</startdate><enddate>20010201</enddate><creator>Takasaki, Ichiro</creator><creator>Andoh, Tsugunobu</creator><creator>Nojima, Hiroshi</creator><creator>Shiraki, Kimiyasu</creator><creator>Kuraishi, Yasushi</creator><general>Elsevier Inc</general><general>American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20010201</creationdate><title>Gabapentin Antinociception in Mice with Acute Herpetic Pain Induced by Herpes Simplex Virus Infection</title><author>Takasaki, Ichiro ; Andoh, Tsugunobu ; Nojima, Hiroshi ; Shiraki, Kimiyasu ; Kuraishi, Yasushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e294t-d661d36a529ecfd652bd0b8af6aa87299daede9e40276f5f6eb0aba3d366ae5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Acetates - pharmacology</topic><topic>Amines</topic><topic>Analgesics - pharmacology</topic><topic>Animals</topic><topic>Behavior, Animal - drug effects</topic><topic>Cyclohexanecarboxylic Acids</topic><topic>Drug Tolerance</topic><topic>Female</topic><topic>gamma-Aminobutyric Acid</topic><topic>Herpes Simplex - complications</topic><topic>Herpes Simplex - virology</topic><topic>Herpesvirus 1, Human</topic><topic>Hyperalgesia - drug therapy</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Motor Activity - drug effects</topic><topic>Naltrexone - pharmacology</topic><topic>Narcotic Antagonists - pharmacology</topic><topic>Pain - drug therapy</topic><topic>Pain - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takasaki, Ichiro</creatorcontrib><creatorcontrib>Andoh, Tsugunobu</creatorcontrib><creatorcontrib>Nojima, Hiroshi</creatorcontrib><creatorcontrib>Shiraki, Kimiyasu</creatorcontrib><creatorcontrib>Kuraishi, Yasushi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takasaki, Ichiro</au><au>Andoh, Tsugunobu</au><au>Nojima, Hiroshi</au><au>Shiraki, Kimiyasu</au><au>Kuraishi, Yasushi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gabapentin Antinociception in Mice with Acute Herpetic Pain Induced by Herpes Simplex Virus Infection</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2001-02-01</date><risdate>2001</risdate><volume>296</volume><issue>2</issue><spage>270</spage><epage>275</epage><pages>270-275</pages><issn>0022-3565</issn><eissn>1521-0103</eissn><abstract>The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain. Transdermal infection with herpes simplex virus type-1 (HSV-1) produced nociceptive hypersensitivity of the infected hind paw to innocuous (allodynia) and noxious mechanical stimulation (hyperalgesia) with von Frey filaments. Systemic administration of gabapentin (10–100 mg/kg, peroral) produced a dose-dependent inhibition of both allodynia and hyperalgesia; gabapentin (30–300 mg/kg) did not affect locomotor activity. Intrathecal injection of gabapentin (10–100 μg/animal) also attenuated dose dependently both nociceptive hypersensitivities. In contrast, intraplantar, intracisternal, and intracerebroventricular administration of gabapentin (10–100 μg/animal) had no effect on the HSV-1-induced nociceptive hypersensitivities. Pretreatment with naltrexone (1 mg/kg) inhibited antinociceptive effect of morphine (5 mg/kg), but not gabapentin (100 mg/kg). Repeated administration of morphine (5 mg/kg, four times) led to tolerance of antinociceptive action, whereas gabapentin (100 mg/kg, four times) had antinociceptive effect even after the forth administration. The present results suggest that gabapentin is effective in the treatment of acute herpetic pain without apparent adverse effects, and analgesic action of gabapentin is mainly mediated by actions on the spinal cord.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>11160607</pmid><doi>10.1016/S0022-3565(24)38784-1</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3565 |
ispartof | The Journal of pharmacology and experimental therapeutics, 2001-02, Vol.296 (2), p.270-275 |
issn | 0022-3565 1521-0103 |
language | eng |
recordid | cdi_proquest_miscellaneous_70631873 |
source | Freely Accessible Journals |
subjects | Acetates - pharmacology Amines Analgesics - pharmacology Animals Behavior, Animal - drug effects Cyclohexanecarboxylic Acids Drug Tolerance Female gamma-Aminobutyric Acid Herpes Simplex - complications Herpes Simplex - virology Herpesvirus 1, Human Hyperalgesia - drug therapy Mice Mice, Inbred BALB C Motor Activity - drug effects Naltrexone - pharmacology Narcotic Antagonists - pharmacology Pain - drug therapy Pain - etiology |
title | Gabapentin Antinociception in Mice with Acute Herpetic Pain Induced by Herpes Simplex Virus Infection |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A21%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gabapentin%20Antinociception%20in%20Mice%20with%20Acute%20Herpetic%20Pain%20Induced%20by%20Herpes%20Simplex%20Virus%20Infection&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Takasaki,%20Ichiro&rft.date=2001-02-01&rft.volume=296&rft.issue=2&rft.spage=270&rft.epage=275&rft.pages=270-275&rft.issn=0022-3565&rft.eissn=1521-0103&rft_id=info:doi/10.1016/S0022-3565(24)38784-1&rft_dat=%3Cproquest_pubme%3E70631873%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-e294t-d661d36a529ecfd652bd0b8af6aa87299daede9e40276f5f6eb0aba3d366ae5a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70631873&rft_id=info:pmid/11160607&rfr_iscdi=true |